As before, projection from the biomarker on the 2D plane of Treatments and Classifiers yields the basket design of Vemurafenib (mono- and combination- therapy) targeting the BRAF mutation for the aforementioned non-melanoma cancers (Fig. 6b). This evidence concerns the gene BRAF and cancer.